Table 1.
Patient demographics and disease characteristics
| Ranibizumab | Intravitreal aflibercept | Total n=101 |
||||
|---|---|---|---|---|---|---|
| Rq4 n=25 |
2q4 n=26 |
0.5q4 n=25 |
2q8 n=25 |
IVT-AFL combined n=76 |
||
| Sex | ||||||
| Male, n (%) | 20 (80.0) | 23 (88.5) | 17 (68.0) | 19 (76.0) | 59 (77.6) | 79 (78.2) |
| Female, n (%) | 5 (20.0) | 3 (11.5) | 8 (32.0) | 6 (24.0) | 17 (22.4) | 22 (21.8) |
| Age (years) | ||||||
| Mean (SD) | 72.0 (6.6) | 70.1 (8.0) | 73.7 (10.1) | 70.6 (7.8) | 71.4 (8.7) | 71.6 (8.2) |
| Range | 60–86 | 56–82 | 58–89 | 58–84 | 56–89 | 56–89 |
| 50–<65, n (%) | 3 (12.0) | 7 (26.9) | 6 (24.0) | 5 (20.0) | 18 (23.7) | 21 (20.8) |
| 65–<75, n (%) | 14 (56.0) | 9 (34.6) | 6 (24.0) | 13 (52.0) | 28 (36.8) | 42 (41.6) |
| ≥75, n (%) | 8 (32.0) | 10 (38.5) | 13 (52.0) | 7 (28.0) | 30 (39.5) | 38 (37.6) |
| BCVA (ETDRS letters) | ||||||
| Mean (SD) | 56.2 (11.7) | 58.8 (11.2) | 48.3 (13.7) | 54.2 (14.5) | 53.8 (13.7) | 54.4 (13.2) |
| Range | 22–74 | 34–79 | 14–68 | 20–74 | 14–79 | 14–79 |
| CRT (µm) | ||||||
| Mean (SD) | 321.2 (113.8) | 327.6 (97.0) | 354.6 (159.6) | 345.4 (185.9) | 342.4 (149.9) | 337.1 (141.6) |
| Range | 175–580 | 128–586 | 142–761 | 161–868 | 128–868 | 128–868 |
| CNV area (mm2) | ||||||
| Mean (SD) | 8.06 (7.49) | 5.07 (4.45) | 5.46 (3.82) | 6.86 (4.42) | 5.79 (4.26) | 6.35 (5.29) |
| Range | 1.0–28.8 | 0.1–16.3 | 0.7–16.2 | 0.5–15.4 | 0.1–16.3 | 0.1–28.8 |
| Total lesion size (mm2) | ||||||
| Mean (SD) | 8.73 (8.19) | 5.47 (4.98) | 6.09 (4.23) | 7.54 (4.79) | 6.35 (4.70) | 6.94 (5.81) |
| Range | 1.1–28.8 | 0.1–20.8 | 1.3–16.2 | 0.5–15.9 | 0.1–20.8 | 0.1–28.8 |
| Lesion type | ||||||
| Occult, n (%) | 10 (40.0) | 12 (46.2) | 11 (44.0) | 12 (48.0) | 35 (46.1) | 45 (44.6) |
| Minimally classic, n (%) | 12 (48.0) | 10 (38.5) | 8 (32.0) | 7 (28.0) | 25 (32.9) | 37 (36.6) |
| Predominantly classic, n (%) | 3 (12.0) | 4 (15.4) | 6 (24.0) | 6 (24.0) | 16 (21.1) | 19 (18.8) |
BCVA, best-corrected visual acuity; CNV, choroidal neovascularisation; CRT, central retinal thickness; ETDRS, Early Treatment of Diabetic Retinopathy Study; IVT-AFL, intravitreal aflibercept.